Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence

Background: Currently, limited data on targeted therapy and immunotherapy sequencing in patients with BRAF-mutant melanoma is available. Targeted therapy and immunotherapy are expected to be comparable in terms of overall survival (OS) when used as second-line therapies; therefore, understanding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogala, Paweł, Czarnecka, Anna M., Cybulska-Stopa, Bożena, Ostaszewski, Krzysztof, Piejko, Karolina, Ziętek, Marcin, Dziura, Robert, Rutkowska, Ewa, Galus, Łukasz, Kempa-Kamińska, Natasza, Calik, Jacek, Sałek-Zań, Agata, Zemełka, Tomasz, Bal, Wiesław, Kamycka, Agnieszka, Świtaj, Tomasz, Kamińska-Winciorek, Grażyna, Suwiński, Rafał, Mackiewicz, Jacek, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/
https://www.ncbi.nlm.nih.gov/pubmed/35456332
http://dx.doi.org/10.3390/jcm11082239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032972/
https://www.ncbi.nlm.nih.gov/pubmed/35456332
http://dx.doi.org/10.3390/jcm11082239

Ejemplares similares